Seizert Capital Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Seizert Capital Partners’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,370	Closed	-$327K	–	204
2022 Q2	$327K	Hold	7,370	–	–	0.02%	183
2022 Q1	$365K	Hold	7,370	–	–	0.02%	179
2021 Q4	$375K	Buy	+7,370	New	+$382K	0.02%	185
2020 Q3	–	Sell	-19,848	Closed	-$952K	–	221
2020 Q2	$952K	Sell	19,848 -3,298	-14%	-$165K	0.06%	116
2020 Q1	$1.06M	Sell	23,146 -2,030	-8%	-$102K	0.08%	105
2019 Q4	$1.51M	Buy	+25,176	New	+$1.5M	0.08%	106

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Seizert Capital Partners's EGRX Position: Q3 2022 in Review

Seizert Capital Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2022, closing a stake of 7,370 shares — an estimated $327K sold.

Seizert Capital Partners first reported a position in EGRX in Q4 2019 and held it in 6 quarters. The position peaked at $1.51M in Q4 2019. 153 funds tracked by Wall St. Rank hold EGRX as of Q3 2022.

Seizert Capital Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
Seizert Capital Partners sold 7,370 Eagle Pharmaceuticals, Inc. shares in Q3 2022, an estimated $327K.
Seizert Capital Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2019 and held it in 6 quarters.
Seizert Capital Partners's Eagle Pharmaceuticals, Inc. position peaked at $1.51M in Q4 2019.
153 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2022.

Based on Seizert Capital Partners's 13F filing for Q3 2022, filed 2 Nov 2022.